Feature


Nature Biotechnology 25, 631 - 638 (2007)
Corrected online: 7 December 2010 | doi:10.1038/nbt0607-631



There is an Erratum (May 2011) associated with this Feature.

MicroRNA gets down to business

George S Mack1


Drugs targeting microRNAs lie some way off, but diagnostics look promising and commercial interest is growing.

Top
  1. George S. Mack is a freelance writer based in Columbia, South Carolina. e-mail: gmack@InfoAve.net
* In the version of the article originally published, reference 8 incorrectly listed Chang, D.Z. as the first author. It should have read Tsuda, N. The error has been corrected in the HMTL and PDF versions of the article.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.